Stage III Prostate Adenocarcinoma Clinical Trial
Official title:
Feasibility of Repeat Targeted Biopsies in Patients Undergoing High-Dose-Rate Prostate Brachytherapy
This pilot clinical trial studies targeted biopsies in determining response in patients with prostate cancer undergoing high-dose-rate brachytherapy (a type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor). Studying tumor tissue obtained before and after treatment may help doctors understand changes in a pathway that looks at how deoxyribonucleic acid (DNA) is repaired after it is damaged and to see if there are differences in the prostate tissue prior to and after starting androgen deprivation therapy.
PRIMARY OBJECTIVES:
I. Demonstrate feasibility of obtaining adequate tumor tissue from an intra-prostatic index
lesion prior to the start of androgen deprivation therapy (ADT) and again at the time of
high-dose-rate (HDR) brachytherapy.
SECONDARY OBJECTIVES:
I. Use immunohistochemistry to stain cells pre-ADT and post 2 months of ADT for markers of
non-homologous end joining and DNA double strand breaks using the following markers: Ku70,
Ku80, DNA-dependent protein kinase catalytic subunits (PKCs), gamma-histone family, member X
(H2AX).
OUTLINE:
Patients undergo biopsy at baseline before start of ADT and during brachytherapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02446366 -
Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery
|
N/A | |
| Completed |
NCT02472275 -
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
|
Phase 1 | |
| Recruiting |
NCT02949284 -
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
|
Phase 2 | |
| Active, not recruiting |
NCT03274687 -
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03070886 -
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03371719 -
BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
|
Phase 2 | |
| Completed |
NCT02678351 -
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
|
Phase 2/Phase 3 | |
| Completed |
NCT03113617 -
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
|
Phase 2 |